<DOC>
	<DOCNO>NCT00005976</DOCNO>
	<brief_summary>Phase I/II trial study effectiveness pyrazoloacridine plus carboplatin treating patient recurrent glioma . Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell .</brief_summary>
	<brief_title>Pyrazoloacridine Plus Carboplatin Treating Patients With Recurrent Glioma</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose pyrazoloacridine plus carboplatin patient recurrent glioma . II . Determine toxic effect treatment regimen patient . III . Determine safety treatment regimen recommend phase II dose patient receive anticonvulsant . IV . Determine efficacy treatment regimen patient . V. Assess pharmacokinetics metabolism pyrazoloacridine patient . VI . Assess response rate , time progression , time death patient treat regimen . OUTLINE : This three-part , dose-escalation , multicenter study . Patients study 3 stratify accord concurrent anticonvulsant ( yes v ) . STUDY 1 : ( Study 1 close 03/29/02 ) Patients receive carboplatin IV 30 minute pyrazoloacridine IV 3 hour day 1 . Treatment continue every 28 day absence unacceptable toxicity disease progression . Cohorts 3-6 patient receive escalate dos carboplatin pyrazoloacridine maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose-limiting toxicity . STUDY 2 : ( Study 2 close 03/29/02 ) Patients receive treatment give study 1 . Dose escalation perform study 1 determine MTD patient receive concurrent anticonvulsant . STUDY 3 : Patients receive treatment give study 1 2 without dose escalation . Patients follow every 3 month 1 year , every 6 month 4 year , annually 5 year . PROJECTED ACCRUAL : Study 1 : A total 3-21 patient accrue study within 6-20 month . Study 2 : A total 3-12 patient accrue study within 3-18 month . Study 3 : A total 12-37 patient accrue study within 15 month .</detailed_description>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>NSC 366140</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm primary brain glioma Diffuse astrocytoma Gliosarcoma Oligodendroglioma Oligoastrocytoma Progressive disease radiotherapy Measurable evaluable disease MRI CT PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Hematopoietic : Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hemoglobin least 9 g/dL Hepatic : Bilirubin great upper limit normal ( ULN ) SGOT great 2.5 time ULN Renal : Creatinine great 2.0 mg/dL Cardiovascular : No myocardial infarction within past 6 month No congestive heart failure require therapy Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No uncontrolled infection No active malignancy No concurrent severe disease PRIOR CONCURRENT THERAPY : Chemotherapy : At least 4 week since prior chemotherapy ( 6 week nitrosoureas ) No 1 prior adjuvant chemotherapy regimen No prior polifeprosan 20 carmustine implant ( Gliadel wafer ) Study 3 : 1 prior chemotherapy regimen recurrent disease allow Prior nonplatinumcontaining adjuvant chemotherapy allow Prior platinumcontaining adjuvant chemotherapy allow disease progress least 6 month last treatment Endocrine therapy : Nonincreasing dose corticosteroid least 1 week allow Radiotherapy : At least 12 week since prior radiotherapy No prior stereotactic radiosurgery interstitial brachytherapy unless least one lesion outside irradiated area Surgery : No surgical resection since prior radiotherapy chemotherapy unless evidence disease progression lesion outside treatment site Other : Study 1 : ( Study 1 close 03/29/02 ) Must anticonvulsant induce cytochrome P450 ( phenytoin , carbamazepine , barbiturate , primidone ) Study 2 : ( Study 2 close 03/29/02 ) No concurrent anticonvulsant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2003</verification_date>
	<keyword>recurrent adult brain tumor</keyword>
	<keyword>adult glioblastoma</keyword>
	<keyword>adult anaplastic astrocytoma</keyword>
	<keyword>adult anaplastic oligodendroglioma</keyword>
	<keyword>adult mixed glioma</keyword>
	<keyword>adult oligodendroglioma</keyword>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
</DOC>